New, high cost treatments for cancers, immunological and orphan diseases comes with rising patient expectations of access to these medicines. For medical schemes, the fine balancing act of managing these expectations with the funding of these treatments while keeping premiums affordable is becoming increasingly difficult. Recent legal cases around this issue have prompted highly emotive publicity resulting in public sentiment that mostly favours the claimant and does little to initiate a broader discussion on new models for funding and prescribing.
Join us on the 17th May for an IHRM Seminar where Health Law Expert, Elsabe Klinck and industry Actuarial Specialist, Christoff Raath will discuss:
- Balancing the rights of the individual to access these treatments with the rights of other members of the scheme.
- Interpreting the PMB standard with regards to expensive treatments. Is it okay for schemes to revert to what’s available in the state, when PMB ‘best practice’ may be different?
- Managing adverse selection on schemes that fund costly new medicines.
- Negotiating directly with the manufacturer.
Date: 17 May 2019
Time: 08:30 for 09:00 to 11:30
Venue: Glenhove Conference and Training Centre, 52 Glenhove Road, Melrose Estate, Johannesburg Map
Don’t miss this important and topical seminar!